Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on September 1, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $510.72 ($163,432) on September 1, 2026; holds 333,623 after (Indirect).
- Open-market sale: disposed of 825 Common Stock at $511.95 ($422,359) on September 1, 2026; holds 332,798 after (Indirect).
- Open-market sale: disposed of 1,732 Common Stock at $513.12 ($888,721) on September 1, 2026; holds 331,066 after (Indirect).
- Open-market sale: disposed of 3,454 Common Stock at $514.09 ($1,775,676) on September 1, 2026; holds 327,612 after (Indirect).
- Open-market sale: disposed of 1,620 Common Stock at $514.98 ($834,272) on September 1, 2026; holds 325,992 after (Indirect).
- Open-market sale: disposed of 1,469 Common Stock at $516.03 ($758,049) on September 1, 2026; holds 324,523 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $516.62 ($41,330) on September 1, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 1, 2026; holds 18,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,883,839 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-09-01 | Open-market sale | Common Stock | 320 | $511 | $163.4K | 333,623 |
| 2026-09-01 | Open-market sale | Common Stock | 825 | $512 | $422.4K | 332,798 |
| 2026-09-01 | Open-market sale | Common Stock | 1,732 | $513 | $888.7K | 331,066 |
| 2026-09-01 | Open-market sale | Common Stock | 3,454 | $514 | $1.8M | 327,612 |
| 2026-09-01 | Open-market sale | Common Stock | 1,620 | $515 | $834.3K | 325,992 |
| 2026-09-01 | Open-market sale | Common Stock | 1,469 | $516 | $758.0K | 324,523 |
| 2026-09-01 | Open-market sale | Common Stock | 80 | $517 | $41.3K | 324,443 |
| 2026-09-01 | Option exercise/conversion | Stock Option | 9,500 | — | — | 18,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (9,500 shares) |
| 2026-09-01 | Open-market sale (320 shares) |
| 2026-09-01 | Open-market sale (825 shares) |
| 2026-09-01 | Open-market sale (1,732 shares) |
| 2026-09-01 | Open-market sale (3,454 shares) |
| 2026-09-01 | Open-market sale (1,620 shares) |
| 2026-09-01 | Open-market sale (1,469 shares) |
| 2026-09-01 | Open-market sale (80 shares) |
| 2026-09-01 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.